- Home
- Medical Options for Advanced HFpEF/HFmrEF Patients: An Expert-Guided Virtual Ward Round
Medical Options for Advanced HFpEF/HFmrEF Patients: An Expert-Guided Virtual Ward Round
- Heart Failure
- HFpEF
Available Credit:
- 1.00
Course Published On:
Course Expiry Date:
Overview
This virtual ward roundtable offers a comprehensive educational experience for healthcare professionals managing complex HFpEF and HFmrEF patients. Chairing the session, Dr Biykem Bozkurt (Baylor College of Medicine, US) is joined by distinguished experts Dr Muthiah Vaduganathan (Brigham and Women’s Hospital and Harvard Medical School, US) and Prof Pardeep Jhund (University of Glasgow, UK).
During the roundtable, the faculty review two case studies and share their expert perspectives on the presented cases for managing high-risk HFmrEF/HFpEF patients, highlighting gaps and challenges. The discussion includes exploring current guidelines, applying an evidence-based approach and a live audience Q&A.
Support Statement
This programme is supported by an unrestricted educational grant from Bayer.
Disclosure
In compliance with EBAC guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.
The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.
Terms & Conditions
Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.
The session, ‘Medical Options for Advanced HFpEF/HFmrEF Patients: An Expert-Guided Virtual Ward Round’ is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credits.
Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).
Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.
Instruction to Participants
There is no fee for taking part in this online learning activity.
Activities are designed to be completed within 60 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.
To complete the course and claim certification participants must:
- Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions
- Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion
Target Audience
- Cardiologists
- Internists
- Heart Failure Specialists
- General Practitioners
- Nurse Practitioners
- Cardiovascular Nurses
- Allied Healthcare Professionals
Learning Objectives
Upon completion of this activity, participants will be able to:
- Describe the current limitations of HFmrEF/HFpEF GDMT in advanced patients
- Select appropriate patients for advanced medical therapy
- Recall recent trial data for novel therapeutic approaches
- Use expert guidance to develop an evidence-based approach to managing advanced HFmrEF/HFpEF
Module |
Title |
Duration |
Speakers |
|---|---|---|---|
| Session 1 | Introduction and Case Study Results | 9m 8s | Biykem Bozkurt Muthiah Vaduganathan Pardeep Jhund |
| Session 2 | Exploring the Guidelines | 4m 20s | Biykem Bozkurt |
| Session 3 | Applying an Evidence-Based Approach: FINEARTS-HF | 7m 24s | Muthiah Vaduganathan |
| Session 4 | Applying an Evidence-Based Approach: MRAs in HF | 9m 21s | Pardeep Jhund |
| Session 5 | Practical Use of MRAs: Expert Discussion | 12m 33s | Biykem Bozkurt Muthiah Vaduganathan Pardeep Jhund |
| Session 6 | Patient Cases Revisited: How Were They Treated? | 5m 5s | Biykem Bozkurt Muthiah Vaduganathan Pardeep Jhund |
| Session 7 | Audience Q&A | 13m 8s | Biykem Bozkurt Muthiah Vaduganathan Pardeep Jhund |
Introduction and Case Study Results
Duration: 9m 8s
Speakers: Biykem Bozkurt Muthiah Vaduganathan Pardeep Jhund
Practical Use of MRAs: Expert Discussion
Duration: 12m 33s
Speakers: Biykem Bozkurt Muthiah Vaduganathan Pardeep Jhund
Patient Cases Revisited: How Were They Treated?
Duration: 5m 5s
Speakers: Biykem Bozkurt Muthiah Vaduganathan Pardeep Jhund
Medical Options for Advanced HFpEF/HFmrEF Patients: An Expert-Guided Virtual Ward Round's programme has been accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 CME point, equating to 1 hour of learning. Physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™.
Related Courses
- 1.00
Published:
Learning objectives
- Understand the nature of amyloidosis and its effects on various organs, particularly the heart
- Distinguish between light-chain (AL) amyloidosis, wild type TTR amyloidosis and hereditary TTR amyloidosis in terms of their clinical manifestations and their different treatments
- Recognise the novel challenges of managing heart failure in cardiac amyloidosis, including both medical management and the role of devices
- Understand the critically important interaction between haematologists and cardiologists in the therapy of AL amyloidosis
- Develop an understanding of novel therapies currently in clinical trials of TTR and AL amyloidosis
- Identify their own roles and responsibilities in the management TTR and AL amyloidosis as part of a multidisciplinary team
- 0.50
Published:
Learning objectives
- Recall recent trial data for novel disease modifying therapy in HCM
- Describe the evolving guideline directed approach to managing HCM
- Develop an expert-led approach to implementing novel therapy in clinical practice
- Not accredited
Published:
Learning objectives
- Recall guideline recommendations for the use of NT-proBNP in heart failure
- Describe current practices in heart failure diagnosis and the impact on treatment outcomes
- Develop an optimised approach to the timely diagnosis and management of heart failure
- 2.00
Published:
Learning objectives
- Recall clinical evidence and guidelines for the management of CKD patients without diabetes
- Describe current gaps and barriers in evidence-based management for CKD without diabetes
- Apply evidence based-management strategies to a case study
- Use expert-led guidance to develop an optimal management approach to CKD patients without diabetes
- Not accredited
Published:
Learning objectives
- Appraise new updates in heart failure guideline-directed medical therapy (GDMT)
- Apply latest guideline recommendations to patient cases
- Describe barriers preventing early initiation of GDMT
- Identify the roles of nurses and other healthcare professionals to achieve optimal heart failure therapy
- Identify the importance of the nurse/cross-functional team
- Not accredited
Published:
Learning objectives
- Appraise the urgency needed in rapid initiation of GDMT to improve HF outcomes.
- Recognise barriers preventing the use of GDMT in current practice.
- Identify strategies needed to drive implementation of GDMT in clinical practice.
- Not accredited
Published:
Learning objectives
- Explain the relationship between sub-optimal RAASi therapy and poor cardio-renal outcomes
- Identify patients who would benefit from anti-hyperkalaemia medications
- Select appropriate anti-hyperkalaemia treatments across a range of patient profiles
- Adopt anti-hyperkalaemia medications as an approach to prolong optimal RAASi therapy
- Summarise current guideline recommendations on the use of potassium binding agents
- 1.00
Published:
Learning objectives
- Identify individuals likely to have HFpEF from initial presentation
- Refer suspected individuals for specialist assessment
- Initiate GDMT for HF as soon as patients are stable
- Initiate GDMT in HF regardless of EF and phenotype
- Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists
- 1.00
Published:
Learning objectives
- Recall the general approach to diagnosis and stratification of HCM according to the latest guidelines and expert opinion
- Apply advanced echocardiographic methodologies to equivocal HCM diagnoses
- Select appropriate imaging modalities to facilitate accurate risk stratification
- Stratify patients based on specific risk features and disease severity
- Choose suitable treatment modalities for patients based on specific disease features and severity
- 1.00
Published:
Learning objectives
- Review current GDMT in HFrEF and HFpEF
- Describe the relationship between initiation of GDMT and HF outcomes
- Prescribe GDMT according to current international recommendations
- Recall the elements of the Kansas City Cardiomyopathy Questionnaire
- Describe the clinical studies that support the use of functional and QoL measures in practice
- Initiate quality of life and functional improvement measures in routine practice
- Initiate SGLT-2 inhibitors in patients presenting with De novo HF and in patients already on other GDMT
- Adopt shared decision-making with HF patients